"The molecular mechanisms of asymmetric cell division in mycobacteria."

“分枝杆菌不对称细胞分裂的分子机制。”

基本信息

  • 批准号:
    10401858
  • 负责人:
  • 金额:
    $ 41.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-12 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Abstract Tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis (Mtb), is now the leading cause of death by a single infectious agent. One reason for this is that subpopulations of Mtb cells can survive even lengthy chemotherapy, preventing cure of disease. These surviving cells are phenotypically tolerant, but not genetically resistant, to antibiotic therapy. Thus, the ability of genetically identical bacteria to display different phenotypes is a significant obstacle for the treatment of TB. A better understanding of the molecular mechanisms underlying this phenomenon could lead to therapeutic advances for TB and other mycobacterial infections. Much of the heterogeneity begins at mycobacterial cell division. Every time a mycobacterium divides it produces daughters with different characteristics. We have recently discovered that this process is genetically encoded. Deleting a single gene, which we have named lamA, leads to cells that grow and divide more symmetrically and are more uniformly susceptible to certain antibiotics. The function of LamA and how it mediates asymmetric growth and division are unknown. Here, we propose to investigate the molecular function of LamA. Our published and preliminary data show that LamA localizes to the site of division, where it inhibits the maturation of the new growth poles. In addition, we have connected LamA to the phosphorylation state of an essential peptidoglycan synthase, and have discovered that its own localization is regulated by phosphorylation. This leads to our hypothesis that LamA dynamically interrupts an unknown communication relay between the multi-protein complexes that accomplish division and elongation, in a phosphorylation- dependent manner. To test this model, we propose the following aims: (1) define the communication relay between the division and elongation complexes; and, (2) dynamically map the regulatory events that lead to asymmetry. Our innovation is to study a mycobacterial-specific protein that creates heterogeneity in a genetically identical population. We will do so by leveraging our expertise in advanced imaging techniques in combination with more traditional methods. Successful completion of these aims will lead to hypotheses about the function of LamA that can be tested with molecular and biochemical approaches. Further, our results will advance our understanding of the molecular basis of cell-division mediated heterogeneity, which has far- reaching consequences for the treatment of TB. For example, identifying the molecular mechanism(s) that leads to subpopulations of bacteria better able to survive antibiotic therapy will allow us to design drug strategies that target heterogeneity. Such interventions could treat TB more quickly, something that would greatly help reduce the global burden of TB disease.
摘要 结核病(TB),一种由结核分枝杆菌(Mtb)引起的细菌感染,现在是主要原因 一种传染源造成的死亡其中一个原因是Mtb细胞的亚群甚至可以存活, 漫长的化疗,阻止疾病的治愈。这些存活的细胞具有表型耐受性,但 对抗生素治疗有遗传抗性。因此,基因相同的细菌表现出不同的 表型是治疗TB的重大障碍。更好地理解分子 这一现象背后的机制可能导致结核病和其他分枝杆菌的治疗进展, 感染.大部分异质性开始于分枝杆菌细胞分裂。每次分枝杆菌 分裂会产生具有不同特征的女儿。我们最近发现这个过程 基因编码删除一个基因,我们命名为lamA,导致细胞生长和分裂 更对称,对某些抗生素的敏感性更一致。LamA的功能以及它如何 介导的不对称生长和分裂是未知的。在这里,我们建议研究分子 LamA的功能。我们发表的和初步的数据表明,LamA定位于分裂的网站,在那里它 抑制了新增长极的成熟。此外,我们已经将LamA与磷酸化 一种必需的肽聚糖合酶的状态,并已发现其自身的定位受 磷酸化这导致了我们的假设,即LamA动态地中断了未知的通信 在磷酸化中完成分裂和延伸的多蛋白质复合物之间进行中继- 依赖的方式。为了验证该模型,我们提出了以下目标:(1)定义通信中继 之间的分裂和延伸复合物;和,(2)动态映射的调节事件,导致 不对称我们的创新是研究一种分枝杆菌特异性蛋白质, 基因相同的人群。我们将利用我们在先进成像技术方面的专业知识, 与更传统的方法相结合。这些目标的成功完成将导致以下假设: LamA的功能可以通过分子和生化方法进行测试。此外,我们的结果将 推进我们对细胞分裂介导的异质性的分子基础的理解,这已经远远- 对结核病的治疗产生影响。例如,确定分子机制, 导致细菌亚群能够更好地存活抗生素治疗将使我们能够设计药物 针对异质性的战略。这些干预措施可以更快地治疗结核病, 大大有助于减轻结核病的全球负担。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth Hesper Rego其他文献

Elizabeth Hesper Rego的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth Hesper Rego', 18)}}的其他基金

"The molecular mechanisms of asymmetric cell division in mycobacteria."
“分枝杆菌不对称细胞分裂的分子机制。”
  • 批准号:
    10612036
  • 财政年份:
    2020
  • 资助金额:
    $ 41.78万
  • 项目类别:
"The molecular mechanisms of asymmetric cell division in mycobacteria."
“分枝杆菌不对称细胞分裂的分子机制。”
  • 批准号:
    10163125
  • 财政年份:
    2020
  • 资助金额:
    $ 41.78万
  • 项目类别:
Mycobacterial single cell drug susceptibility
分枝杆菌单细胞药物敏感性
  • 批准号:
    8645267
  • 财政年份:
    2014
  • 资助金额:
    $ 41.78万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 41.78万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 41.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了